Caution Regarding Forward-Looking Information





This report includes "forward-looking statements" that are subject to risks,
uncertainties and other factors.  All statements other than statements of
historical fact are statements that could be deemed forward-looking statements
including continued compliance with government regulations, changing legislation
or regulatory environments; any statements of expectation or belief and any
statements of assumptions underlying any of the foregoing. These risks,
uncertainties and other factors, and the general risks associated with the
businesses of the Company described in the reports and other documents filed
with the SEC, could cause actual results to differ materially from those
referred to in the forward-looking statements.  The Company cautions readers not
to rely on these forward-looking statements.  All forward-looking statements are
based on information currently available to the Company and are qualified in
their entirety by this cautionary statement.  The Company anticipates that
subsequent events and developments may cause its views to change.  The
information contained in this report speaks as of the date hereof and the
Company has or undertakes no obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise unless required by law.

Company Overview

Evolutionary Genomics, Inc. (the "registrant" or "Company") was incorporated
under the laws of the state of Minnesota in November 1990 under the name
Fonahome Corporation. On March 24, 2009, the Company reincorporated in the state
of Nevada and merged with its wholly-owned subsidiary, Fona, Inc., adopting the
surviving company's name, Fona, Inc. The capital structure includes total
authorized capital stock of 800,000,000 shares, of which 780,000,000 are common
stock and 20,000,000 are blank check preferred stock. The preferred stock may be
issued from time to time in one or more series with such designations,
preferences and relative participating, optional or other special rights and
qualifications, limitations or restrictions thereof, as shall be stated in the
resolutions adopted by the Corporation's Board providing for the issuance of
such preferred stock or series thereof.


On June 6, 2014, Evolutionary Genomics, Inc., a Delaware corporation merged with
Fona, Inc. treated as a reverse acquisition with Evolutionary Genomics, Inc. as
the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona,
Inc. was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from
Evolutionary Genomics, Inc. to EG Crop Science, Inc. On May 9, 2016, we formed
ICAM Therapeutics, Inc. (a Delaware corporation) as a wholly owned subsidiary of
Evolutionary Genomics, Inc. We have not incurred any transactions in this
company nor have we established any business plan for the future.


The Company maintains headquarters at the office of its Chief Executive Officer.
The Company maintains a website at www.evolgen.com. The Company is not required
to deliver an annual report to security holders and at this time does not
anticipate the distribution of such a report. The Company will file reports with
the SEC.


On August 14, 2000, the Company was issued patent number 6274319, titled
"Methods to identify evolutionarily significant changes in polynucleotide and
polypeptide sequences in domestic plants and animals". On June 1, 2004, the
Company was issued patent number 6743580, titled "Methods for producing
transgenic plants containing evolutionarily significant polynucleotides". These
patents are for the core Adapted Traits Platform that we use for the discovery
of genes in humans, animals and commercial crops. The Company has applied the
Adapted Traits Platform in research projects including identifying genes
believed to be responsible for increases in yield in corn, increases in yield in
rice, salt tolerance and sugar content in tomatoes and pest/disease resistance
in soybeans, bananas and multiple other crops.


In the past century, agriculture has been characterized by enhanced
productivity, the use of synthetic fertilizers and pesticides, selective
breeding, mechanization, water contamination, and farm subsidies. Proponents of
organic farming such as Sir Albert Howard argued in the early 20th century that
the overuse of pesticides and synthetic fertilizers damages the long-term
fertility of the soil. While this feeling lay dormant for decades, as
environmental awareness has increased in the 21st century there has been a
movement towards sustainable agriculture by some farmers, consumers, and
policymakers.


Advances in genetic research and modification of crop species have led to
increased yield, drought tolerance and disease/pest resistance. These advances
have also led to an increased concentration within the providers of seed to the
industry. The top seed companies control much of the implementation of new seed
varieties through patents and licensing agreements. Genetic traits providers,
like Evolutionary Genomics, identify and develop genes that impact traits of
interest to the industry and market those genes to these seed companies.




                                       14



--------------------------------------------------------------------------------



On June 26, 2018, the Company was awarded an Advanced Industries Accelerator
Grant by the State of Colorado in the amount of $250,000 to identify and
validate pathogen resistance genes in bananas and complete validation and
marketing tomato and corn genes. The Company maintains ownership of all
intellectual property developed from the use of grant funds.  The Company has
recognized all revenue from this grant.


Evolutionary Genomics intends to continue to pursue grant funding from
governmental agencies, industry associations and grant making foundations. These
sources of funding are often subject to limitations in available funds, funding
priorities in areas other than our area of focus, political uncertainties, long
approval processes and competition with other research proposals. If such
funding is not available, Evolutionary Genomics may incur the costs of these
projects with the prospect of revenue uncertain and likely many years in the
future.


The single most valuable step in the process of crop improvement is the
identification of the key genes among the 30,000 or more in the genome that has
the desired impact. Evolutionary Genomics' soybean pest resistance project is an
illustration of the evolution of a project from concept through marketing to
seed companies. The project has yielded identified genes for pest resistance in
soybeans and, in hairy root assays on one of these genes, EG261, at the
University of Wisconsin - Madison, proved that EG261 impacted resistance.
Evolutionary Genomics has had discussions with seed companies to commercialize
the genes and intends to continue those discussions after completion of
validation testing with two generation, whole plant validation results. The
Company has extended this pest resistance research to other crops including
beans, tomatoes, cotton and maize in various stages or progress.


On April 29, 2014, the United States Patent and Trademark Office issued patent
8,710,300 titled EXPRESSION OF DIRIGENT GENE EG261 AND ITS ORTHOLOGS AND
PARALOGS ENHANCES PATHOGEN RESISTANCE IN PLANTS. On December 5, 2017, the United
States Patent and Trademark Office issued patent 9,834,783 which extended the
previous patent to include additional variations of the gene. During 2017, the
Company was issued similar patents in Canada, Brazil and China and has
additional patents pending in Argentina and India. On January 16, 2020, the
Company filed a patent application on its second soybean pest/disease resistance
gene, EG19 and has included that gene in its ongoing two generation, whole plant
validation research with the University of Missouri and with the Wisconsin Crop
Innovation Center. Evolutionary Genomics engaged in discussions with seed
companies regarding further validation of the effectiveness of EG261. Based on
information received in those discussions, Evolutionary Genomics has engaged in
a whole plant validation trial of EG261 and EG19 at the University of Missouri
and the Wisconsin Crop Innovation Center.


We previously expected to complete the soybean research in the second quarter of
2020.  Our academic labs informed us that they are not able to perform the SCN
testing due to the COVID-19 pandemic and we now believe that the project will be
delayed until later in 2020.  If this research is not completed within a
reasonable timeframe or within estimated costs, future licensing revenue, the
valuation of our research in progress and the financial condition of the Company
could be significantly impacted. The full impact that COVID-19 will have on our
business will depend on a number of factors such as the duration and extent of
COVID-19, the effect of governmental actions, responses of our third-party
research partners, and general economic activity, as described in Part II, Item
1A "Risk Factors" in this Form 10-Q.


As a small company restricted by our limited resources, we cannot afford to
generate vast numbers of events. Moderate success is important enough to
indicate that further optimization can lead to significantly improved results.
We must prove that there is enough evidence to warrant additional trials by
companies with vastly more resources to build on our success but the single most
valuable step in this process is the identification of the gene that has the
desired impact and we have identified two of these genes in soybeans, EG261 and
EG19.  We cannot assure you that these identified genes will be successful in
SCN testing or field trials.


We entered into a Service Agreement with Wisconsin Crop Innovation Center
("WCIC") under which they have transformed soybeans using our genes. WCIC
guarantees a minimum number of successful events, have helped to establish the
right combinations to achieve a range of expression and tested to assure us of
successful events. WCIC has harvested the seeds of events from seven constructs
of EG261 and EG19. These seeds are being transferred to the University of
Missouri for SCN resistance testing which we now expect to happen later in 2020.




                                       15



--------------------------------------------------------------------------------



If we are able to resume SCN resistance testing and results confirm the findings
of the University of Wisconsin-Madison for EG261 and the effectiveness of the
new gene, EG19, the Company will look to enter into negotiations for a long-term
research collaboration and licensing agreement with seed companies. This type of
agreement will likely have an upfront payment, milestone payments during their
testing and a licensing royalty stream once the genes are incorporated into
commercial seed lines. The testing phase includes field trials which may proceed
for several years prior to generating licensing revenue. There are many risks in
this process including some that are outside of Evolutionary Genomics' control
and there can be no guarantee that we will ever generate any revenue from these
potential agreements. If Evolutionary Genomics receives product royalties from
the soybean genes, it is required to pay the United Soybean Board a ten percent
royalty stream not to exceed 150% of the grant amount of $262,400.


The Company has identified pest/disease resistance genes in other commercially
valuable crops. The Company is currently engaged with the University of Missouri
to perform two generation, whole plant testing of genes in tomatoes and corn
that may lead to increased pest/disease resistance. This project is currently on
hold pending results from our soybean project and the availability of funding.
If successful, we intend to market them to the seed industry. This strategy will
require Evolutionary Genomics to incur significant research costs prior to any
confirmation of commercial viability and there can be no guarantee that the
desired results can be achieved or that commercialization can be reached.


Evolutionary Genomics has identified a gene in tomatoes that impacts the plant's
ability to tolerate salt and a gene that appears to control sweetness. On
January 9, 2018, the United States Patent and Trademark Office issued patent
9,862,962 titled IDENTIFICATION AND USE OF TOMATO GENES CONTROLLING SALT/DROUGHT
TOLERANCE AND FRUIT SWEETNESS. Despite discussions with seed companies, the
Company has not been able to reach any agreement to license these genes and
there can be no assurance that we will ever realize any revenue from these
genes.


In 2014, the Company began a project to identify genes in cotton that may impact
traits of commercial interest. In particular, we intend to focus on pest
resistance and fiber length. We have used our Adapted Traits Platform to
identify positively selected candidate genes and intend to further research
these genes to confirm that they were positively selected. If any of these genes
remain promising, we intend to contract with an independent lab to validate the
effectiveness of those genes. These studies can be very costly and there can be
no assurance that we will be successful with this project.


During the 1950s the global banana industry was devastated by a disease (caused
by Fusarium fungus) that effectively wiped out the predominate variety of
commercial bananas know as Gros Michel leading to the development of the
Cavendish banana, which makes up well over 90% of the commercial banana market
today. Cavendish was resistant to the strain of Fusarium that wiped out the Gros
Michel variety but, in recent years, is being challenged by a new race of
Fusarium that threatens to, once again, devastate the global banana industry.
This crisis is imminent and has no solution. The recent emergence of Panama
Disease TR4 in the Western Hemisphere makes a swift solution to the crisis even
more urgent.  A substantial part of the banana market consists of exports from
Central and South America to the United States. This market is now critically
imperiled.


In 2018, the Company began a project to identify genes in wild banana relatives
that are resistant to Fusarium. We have previously used our technology to
identify genes in common beans and, in our project for the Bill and Melinda
Gates Foundation in common beans, proved that these genes provided increased
resistance to Fusarium fungus. We used our platform to isolate a banana gene
that controls Fusarium Wilt (FW), aka Panama Disease, Tropical Race 4. The gene,
which we have named FusR1 (Fusarium Resistance 1), is a native gene in Musa
species, including cultivated bananas. We have found that, for all FW-resistant
banana cultivars/species that we have tested, one version of our gene exists
while, in all FW-sensitive banana cultivars/species that we have tested, there
is a different version of FusR1. And notably, a third version exists in
semi-resistant varieties that has allowed us to identify the particular
nucleotide changes that are crucial for resistance to Fusarium Wilt.


We believe that this native banana gene can be introduced into cultivated
bananas, particularly the Fusarium-sensitive Cavendish cultivar in order to make
these cultivars resistant to Fusarium Wilt.  Cavendish cultivars are sterile and
seedless, but it should be possible to use MAB (marker assisted breeding),
though perhaps difficult and time-consuming, to move FusR1 into Cavendish and
other cultivated bananas. We believe that a gene transformation approach would
be faster and easier. Given the threat of possible extinction for Cavendish,
rapid approaches are not only warranted but essential and minimally genetically
edited bananas will be accepted depending upon how the gene transfer is
accomplished. Transfer of this native banana gene to cultivated bananas can also
be accomplished with CRISPR technology, which allows a targeted, clean, and
efficient transfer and which, as compared to more traditional genetic editing
techniques, minimizes potential side effects.  We believe that Cavendish bananas
can be rendered Fusarium Wilt resistant by changing only a few base pairs. These
sorts of minimal changes have been allowed by the USDA and FDA in several crops.
Even in Europe, use of CRISPR technology has gained substantial traction.



                                       16



--------------------------------------------------------------------------------

On June 26, 2019, we filed a United States patent application titled IDENTIFICATION AND RESISTANCE GENES FROM WILD RELATIVES OF BANANA AND THEIR USES IN CONTROLLING PANAMA DISEASE.




On August 19, 2020, the Company entered into a Development and Commercialization
Agreement with Dole Food Company for the development of plant varieties within
the Musa genus of the Musaceae family (including the Cavendish variety of
banana) that exhibit resistance to Fusarium Wilt Tropical Race 4 (popularly
known as Panama Disease).  Subject to compliance with various provisions of the
agreement, the agreement includes working capital funding from Dole to the
Company over the next four years. In addition to working capital funding, Dole
will reimburse the Company for the development of banana plants and incur
additional costs for the commercialization of plants upon successful completion
of the development portion of this project. Per the Agreement, 50% of future
royalties may be offset with the research funding provided by Dole. In the event
that Dole terminates the agreement for material breach by the Company or the
Company's bankruptcy, the Company must repay all funding provided by Dole
balances to Dole within six months of termination. The parties have agreed to
negotiate the terms of the long-term license agreement upon successful
completion of the development portion of this project. We expect that the
funding from these sources will be more than enough to cover our operating
expenses for the next twelve months.  If the funding does not arrive per the
agreement, the Company may not be able to meet its obligations as they become
due.


If we are able to successfully transform and validate our banana genes, which
will likely take 24-36 months, under the terms of the agreement with Dole, we
expect to negotiate a long term royalty contract for the commercialization of
banana plants using our genes.  This licensing arrangement will likely be
exclusively with Dole and contain royalty payments based on the number of plants
and/or hectares of plants.  Even if EG's genes are proved to be effective, it is
difficult to predict the future revenue stream that any licensing arrangement
can generate and will be heavily dependent upon the speed with which Panama
Disease spreads throughout the world necessitating a solution and any changes in
the price of bananas based on supply and demand.  Many articles are available in
the public realm detailing the significance of the disease and the spread
throughout the world.


Since bananas are seedless, they are propagated by clones which allows for very
rapid production of plants.  An initial batch of 100 successful plants can
generate a secondary propagation of over 15,000 plants in one year (enough for
10 hectares) and 15 million in the next generation.  There are over 400,000
hectares of banana production in Latin America from Mexico to Peru.  Adoption of
the new variety will be dependent upon its effectiveness and the infection rate
of Panama disease.

There are many risks associated with achieving these desired results including but not limited to:




       -  We may not be able to adequately establish patent protection for our
          intellectual property or others may have competing claims;
       -  Others may develop competitive approaches to compete with our genes;

- Our transformation academic labs may fail to develop enough events for

testing;

- Our genes may cause unforeseen and undesirable changes beyond the pest


          resistance such as yield degradation or changes in the appearance or
          taste of the fruit;
       -  Our genes may fail to deliver the desired results of resistance to
          Fusarium;
       -  Globally regulations and/or consumer preference may prevent the

successful commercial launch of bananas with genetics changed using our

methods; and

- We will be dependent on others for the successful production and

marketing of bananas with our genes and many factors will be outside of

our control.

- Our cash flow is highly dependent upon our only expected source of

funding provided under our Development and Commercialization Agreement


          with Dole Food Company.
       -  Our expected future royalty revenue will be highly dependent upon the
          successful execution of the banana development project in the

Development and Commercialization Agreement with Dole Food Company and

the negotiation of a long term royalty licensing agreement expected in

the third year of that agreement.

These and other risk factors are discussed in more detail in our 10-K filing dated March 30, 2020.

Evolutionary Genomics has no registered trademarks. The Company had two full
time employees and one part-time employee as of June 30, 2020 and leases its
operating facility on a month-to-month basis after June 30, 2017. Evolutionary
Genomics is not currently involved in or aware of any threatened or actual legal
proceedings.




                                       17



--------------------------------------------------------------------------------

Unaudited Results of Operations




                                Three Months Ended June 30,                                   Six Months Ended June 30,
                            2020                           2019                           2020                          2019
                                 Percent of                     Percent of                    Percent of                     Percent of
                   Amount         Revenue          Amount        Revenue         Amount         Revenue         Amount        Revenue
Grant revenue    $        -              N/A     $   50,753          100.0 %   $   12,500           100.0 %   $   83,119          100.0 %
Research and
development         167,526              N/A        113,658          223.9

% 260,748 2086.0 % 245,342 295.2 % Salaries and benefits

             93,229              N/A         42,062           82.9

% 185,659 1485.3 % 96,841 116.5 % General and administrative 49,842

              N/A         66,360          130.8 %      106,507           852.1 %      124,614          149.9 %

Total

operating


expenses            310,597              N/A        222,080          437.6

% 552,914 4423.3 % 466,797 561.6 % Operating loss (310,597 )

            N/A       (171,327 )       -337.6 %     (540,414 )       -4323.3 %     (383,678 )       -461.6 %
Other income
and (expenses)       15,799              N/A        (10,418 )        -20.5 %        3,800            30.4 %        1,536            1.8 %
Income Taxes              -              N/A              -            0.0 %            -             0.0 %            -            0.0 %
Net loss         $ (294,798 )            N/A     $ (181,745 )       -358.1

% $ (536,614 ) -4292.9 % $ (382,142 ) -459.8 % Preferred stock dividend (71,392 )

            N/A        (66,004 )       -130.0 %     (142,783 )       -1142.3 %     (126,595 )       -152.3 %
Net loss
attributable
to common
stockholders     $ (366,190 )            N/A     $ (247,749 )       -488.1

% $ (679,397 ) -5435.2 % $ (508,737 ) -612.1 %





Service and Grant Revenue


Service revenue decreased $70,619, or 85.0%, to $12,500 for the six months ended
June 30, 2020 from $83,119 for the six months ended June 30, 2019. The decrease
was due to decreased revenue recognized from the State of Colorado grant which
ended in January 2020.

Service revenue decreased $50,753, or 100.0%, to $0 for the three months ended June 30, 2020 from $50,753 for the three months ended June 30, 2019. The decrease was due to decreased revenue recognized from the State of Colorado grant which ended in January 2020.

Operating Expenses

Operating expenses increased $86,117, or 18.4% to $552,914 for the six months ended June 30, 2020 from $466,797 for the six months ended June 30, 2019. Changes in these items are described below.

Operating expenses increased $88,517, or 39.9% to $310,597 for the three months ended June 30, 2020 from $222,080 for the three months ended June 30, 2019. Changes in these items are described below.

Research and Development




Research and development increased $15,406, or 6.3%, to $260,748 for the six
months ended June 30, 2020 from $245,342 for the six months ended June 30, 2019.
The increase was primarily due to increased patent costs partially offset by
decreased costs for our soybean pest resistance project and our banana disease
resistance project.


Research and development increased $53,868, or 47.4%, to $167,526 for the three
months ended June 30, 2020 from $113,658 for the three months ended June 30,
2019. The increase was primarily due to increased costs on our soybean pest
resistance project and higher patent costs partially offset by decreased costs
for our banana disease resistance project.

Salaries and Benefits

Salaries and benefits increased $88,818, or 91.7%, to $185,659 for the six months ended June 30, 2020 from $96,841 for the six months ended June 30, 2019. The increase was primarily due to increased stock compensation costs.





                                       18



--------------------------------------------------------------------------------

Salaries and benefits increased $51,167, or 121.6%, to $93,229 for the three months ended June 30, 2020 from $42,062 for the three months ended June 30, 2019. The increase was primarily due to increased stock compensation costs.

General and Administrative




General and administrative expenses decreased $18,107, or 14.5%, to $106,507 for
the six months ended June 30, 2020 from $124,614 for the six months ended June
30, 2019. The decrease was primarily due to decreased professional fees.


General and administrative expenses decreased $16,518, or 24.9%, to $49,842 for
the three months ended June 30, 2020 from $66,360 for the three months ended
June 30, 2019. The decrease was primarily due to one quarter of directors' fees
in the three months ended June 30, 2020 compared to two quarters of directors'
fees that were paid in the three months ended June 30, 2019.

Other Income and (Expenses)




Total other income and (expense) increased $2,264, or 147.4%, to $3,800 of
income for the six months ended June 30, 2020 from $1,536 of income for the six
months ended June 30, 2019. The increase was primarily due to an increase in the
market price of marketable securities.


Total other income and (expense) increased $26,217, or 251.7%, to $15,799 of
income for the three months ended June 30, 2020 from ($10,418) of expense for
the three months ended June 30, 2019. The increase was primarily due to an
increase in the market price of marketable securities.

Net Loss




Net loss increased $154,472, or 40.4%, to $536,614 for the six months ended June
30, 2020 from $382,142 for the six months ended June 30, 2019. The increase was
primarily due to decreased revenue from the State of Colorado grant, increased
patent costs, increased stock compensation costs and increased professional fees
and partially offset by decreased costs on our soybean and banana projects and
an increase in the market price of marketable securities.


Net loss increased $113,053, or 62.2%, to $294,798 for the three months ended
June 30, 2020 from $181,745 for the three months ended June 30, 2019. The
increase was primarily due to decreased revenue from the State of Colorado
grant, increased patent costs, increased soybean project costs and increased
stock compensation costs partially offset by decreased costs on our banana
project and an increase in the market price of marketable securities.

Financial Condition




The Company's working capital decreased $213,470 to ($114,722) as of June 30,
2020 from $98,748 as of December 31, 2019 primarily due the net loss partially
offset by an increase in accounts payable and accrued expenses and proceeds from
notes payable.


Liquidity


The Company has historically financed operations through cash flows from
operations and equity transactions. Net cash used in operating activities was
$267,258 for the six months ended June 30, 2020 compared to $326,443 for the six
months ended June 30, 2019. The $59,185, or 18.1%, decrease was primarily due to
an increase in accounts payable and an increase in stock compensation partially
offset by the increased net operating loss. Net cash flows for investing
activities was $0 for the six months ended June 30, 2020 and 2019. Net cash
provided from financing activities was $224,268 of proceeds from notes payable
for the six months ended June 30, 2020 and $540,015 of proceeds from the
issuance of preferred stock in the six months ended June 30, 2019.


Sources of funding to meet prospective cash requirements include the Company's
existing cash balances and investments along with funding from our agreement
with Dole Fruit. As of June 30, 2020 we had $2,451 in our bank accounts and
$45,493 of trading securities. On April 17, 2020, the Company received $71,268
in funding from the SBA under their Paycheck Protection Program. To the extent
the loan is not forgiven, the loan accrues interest at 1 percent and has monthly
payments of $4,010.75 starting October 16, 2020.




                                       19



--------------------------------------------------------------------------------



On August 19, 2020, the Company entered into a Development and Commercialization
Agreement with Dole Food Company for the development of plant varieties within
the Musa genus of the Musaceae family (including the Cavendish variety of
banana) that exhibit resistance to Fusarium Wilt Tropical Race 4 (popularly
known as Panama Disease).  Subject to compliance with various provisions of the
agreement, the agreement includes working capital funding from Dole to the
Company over the next four years. In addition to working capital funding, Dole
will reimburse the Company for the development of banana plants and incur
additional costs for the commercialization of plants upon successful completion
of the development portion of this project. Per the Agreement, 50% of future
royalties may be offset with the research funding provided by Dole. In the event
that Dole terminates the agreement for material breach by the Company or the
Company's bankruptcy, the Company must repay all funding provided by Dole
balances to Dole within six months of termination. The parties have agreed to
negotiate the terms of the long-term license agreement upon successful
completion of the development portion of this project. We expect that the
funding from these sources will be more than enough to cover our operating
expenses for the next twelve months.  If the funding does not arrive per the
agreement, the Company may not be able to meet its obligations as they become
due.

Off-Balance Sheet Arrangements




The Company has no off-balance sheet arrangements that have a material current
effect, or that are reasonably likely to have a material future effect, on its
financial condition, changes in financial condition, revenue or expenses,
results of operations, liquidity, capital expenditures, or capital resources.


Contractual Obligations


The Company leases its operating facility and pays its rent in monthly
installments. The lease was renewed in June 2016 for a period of twelve months
and monthly rentals for the period of July 1, 2016 through December 31, 2019 are
$2,378 per month which continues on a month-to-month basis. There is no minimum
lease commitment as of June 30, 2020. Renewals after June 30, 2017 are by mutual
agreement. The Company's rent expense for the three months ended June 30, 2020
and 2019 was $14,268 and $14,268, respectively.


On February 21, 2015, Evolutionary Genomics entered into a Sponsored Research
Contract with The Curators of the University of Missouri for phenotyping
transgenic soybean plants.  As amended the contract calls for payments to be
made on a per plant basis with no minimum future payments.  We expect to
continue this contract and will likely have additional amounts payable but the
amount is indeterminable.


ITEM 3.

© Edgar Online, source Glimpses